UBS Group Issues Positive Forecast for LifeStance Health Group (NASDAQ:LFST) Stock Price

LifeStance Health Group (NASDAQ:LFST) had its price objective raised by UBS Group from $9.00 to $10.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s price objective would indicate a potential upside of 60.13% from the company’s current price.

Several other research analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of LifeStance Health Group from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Weiss Ratings restated a “sell (e+)” rating on shares of LifeStance Health Group in a research report on Wednesday, October 8th. Finally, BTIG Research boosted their target price on LifeStance Health Group from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, LifeStance Health Group presently has a consensus rating of “Moderate Buy” and an average price target of $8.83.

LifeStance Health Group Price Performance

LFST traded down $0.01 during trading on Friday, reaching $6.25. The stock had a trading volume of 2,219,012 shares, compared to its average volume of 1,983,409. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.48 and a current ratio of 1.48. LifeStance Health Group has a one year low of $3.74 and a one year high of $8.30. The business has a 50-day moving average of $5.29 and a 200-day moving average of $5.27. The stock has a market cap of $2.43 billion, a PE ratio of -124.30 and a beta of 1.15.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. LifeStance Health Group had a negative net margin of 1.23% and a negative return on equity of 1.11%. The company had revenue of $363.81 million during the quarter, compared to the consensus estimate of $355.06 million. During the same period in the prior year, the firm earned ($0.02) earnings per share. LifeStance Health Group’s revenue was up 16.3% on a year-over-year basis. LifeStance Health Group has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts anticipate that LifeStance Health Group will post -0.18 EPS for the current fiscal year.

Insider Buying and Selling at LifeStance Health Group

In related news, major shareholder Silversmith Partners I. Gp, Llc sold 3,592,357 shares of the company’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.07, for a total value of $18,213,249.99. Following the completion of the sale, the insider owned 14,324,197 shares in the company, valued at approximately $72,623,678.79. This represents a 20.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Darren M. Black sold 8,407,643 shares of LifeStance Health Group stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.07, for a total value of $42,626,750.01. Following the transaction, the director owned 33,524,715 shares in the company, valued at approximately $169,970,305.05. This represents a 20.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 20,407,643 shares of company stock valued at $103,466,750 in the last ninety days. Company insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of LifeStance Health Group by 19.5% in the third quarter. Vanguard Group Inc. now owns 14,613,535 shares of the company’s stock valued at $80,374,000 after purchasing an additional 2,383,728 shares during the last quarter. Jennison Associates LLC raised its stake in LifeStance Health Group by 2.1% in the first quarter. Jennison Associates LLC now owns 8,255,236 shares of the company’s stock valued at $54,980,000 after buying an additional 168,856 shares during the period. Wellington Management Group LLP lifted its position in shares of LifeStance Health Group by 2.3% in the first quarter. Wellington Management Group LLP now owns 5,399,293 shares of the company’s stock valued at $35,959,000 after buying an additional 123,056 shares during the last quarter. AustralianSuper Pty Ltd acquired a new stake in LifeStance Health Group during the 3rd quarter valued at $17,056,000. Finally, Qube Research & Technologies Ltd boosted its position in LifeStance Health Group by 90.5% during the second quarter. Qube Research & Technologies Ltd now owns 2,455,027 shares of the company’s stock worth $12,692,000 after purchasing an additional 1,166,045 shares during the period. 85.50% of the stock is owned by institutional investors and hedge funds.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.